Rapport Therapeutics (RAPP) Liabilities and Shareholders Equity (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $497.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 64.74% year-over-year to $497.6 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 41.46% increase from a year earlier, with the FY2025 full-year figure at $512.4 million, up 62.71% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $497.6 million, down from $512.4 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RAPP reached as high as $535.3 million in Q3 2025 and fell as low as $155.4 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $364.5 million across 4 years, with a median of $331.1 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity jumped 102.63% in 2024 and slipped 17.51% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $155.4 million in 2023, then surged by 102.63% to $314.9 million in 2024, then jumped by 62.71% to $512.4 million in 2025, then slipped by 2.89% to $497.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $497.6 million in Q1 2026, $512.4 million in Q4 2025, and $535.3 million in Q3 2025.